AstraZeneca is a global pharmaceutical company harnessing the power of science to make health
happen for people, society and the planet. We follow the science to create
transformative change, primarily for the treatment of diseases in four main therapy areas -
Oncology, Cardiovascular & Metabolic Disease, Respiratory and Rare Disease. We are also
selectively active in the areas of autoimmunity, neuroscience and infection.
AstraZeneca Hong Kong oversees both the Hong Kong and Macau markets and attaches a strong importance to them. Since its inception in 1990, AstraZeneca Hong Kong has delivered many life-changing medicines that have transformed the lives of patients and have revolutionized disease treatment in Hong Kong and Macau. Over the years, we have been continually expanding our business in order to meet the growing demand of the markets.
To make health happen for as many people, in as many ways, as possible, we ensure that our medicines can reach the people that need them and minimise the economic burden of delivering them. We push the boundaries of science to deliver life-changing medicines for the world’s most serious health challenges. We ensure broad access to our life-changing medicines, working to ensure that every eligible person, no matter their personal circumstances, can be connected with the right treatment. We have provided different Patient Affordability Programs in collaboration with local associations in the past years. We are also working with different non-governmental organizations (NGOs) to provide patient empowerment programs in Respiratory, Diabetes, Cardiovascular and Cancer diseases.
Making health happen for society has never been more important. AstraZeneca Hong Kong partners with governments and others to advance healthcare systems and economies. As a strategic partner to the HKSAR Office of Attracting Strategic Enterprises and the Hong Kong-Shenzhen Innovation and Technology Park, we continuously explore innovative healthcare solution to prevent health threats, diagnose patients earlier, and provide treatment in their homes and communities, thereby reducing the pressure on health systems. Since 2023, we have established the Global R&D China Hong Kong Center and the Hong Kong iCampus to co-build a biotech ecosystem. Over the past 35 years, we have launched more than 100 products and conducted over 100 clinical studies, including more than 30 breakthrough studies, positively impacting the health of over 6,000,000 patients.
As AstraZeneca continues to grow across all therapy areas, we are also committed to make health happen for the planet by aiming to achieve science-based net zero by 2045 at the latest.
Our strategic priorities are to deliver growth and TA leadership, accelerate innovative science and be a great place to work. As we celebrate our past accomplishments, we are confident about the future– because of our people, our partners and our firm commitment to pushing the boundaries of science to deliver life-changing medicines. Looking ahead, we will continue focus on sustainable development and the delivery of a flow of new medicines that make a difference in the lives of patients in Hong Kong and around the world.
For more information about AstraZeneca, please go to: www.astrazeneca.com.
HK-12051 2025/07/09
AstraZeneca Hong Kong oversees both the Hong Kong and Macau markets and attaches a strong importance to them. Since its inception in 1990, AstraZeneca Hong Kong has delivered many life-changing medicines that have transformed the lives of patients and have revolutionized disease treatment in Hong Kong and Macau. Over the years, we have been continually expanding our business in order to meet the growing demand of the markets.
To make health happen for as many people, in as many ways, as possible, we ensure that our medicines can reach the people that need them and minimise the economic burden of delivering them. We push the boundaries of science to deliver life-changing medicines for the world’s most serious health challenges. We ensure broad access to our life-changing medicines, working to ensure that every eligible person, no matter their personal circumstances, can be connected with the right treatment. We have provided different Patient Affordability Programs in collaboration with local associations in the past years. We are also working with different non-governmental organizations (NGOs) to provide patient empowerment programs in Respiratory, Diabetes, Cardiovascular and Cancer diseases.
Making health happen for society has never been more important. AstraZeneca Hong Kong partners with governments and others to advance healthcare systems and economies. As a strategic partner to the HKSAR Office of Attracting Strategic Enterprises and the Hong Kong-Shenzhen Innovation and Technology Park, we continuously explore innovative healthcare solution to prevent health threats, diagnose patients earlier, and provide treatment in their homes and communities, thereby reducing the pressure on health systems. Since 2023, we have established the Global R&D China Hong Kong Center and the Hong Kong iCampus to co-build a biotech ecosystem. Over the past 35 years, we have launched more than 100 products and conducted over 100 clinical studies, including more than 30 breakthrough studies, positively impacting the health of over 6,000,000 patients.
As AstraZeneca continues to grow across all therapy areas, we are also committed to make health happen for the planet by aiming to achieve science-based net zero by 2045 at the latest.
Our strategic priorities are to deliver growth and TA leadership, accelerate innovative science and be a great place to work. As we celebrate our past accomplishments, we are confident about the future– because of our people, our partners and our firm commitment to pushing the boundaries of science to deliver life-changing medicines. Looking ahead, we will continue focus on sustainable development and the delivery of a flow of new medicines that make a difference in the lives of patients in Hong Kong and around the world.
For more information about AstraZeneca, please go to: www.astrazeneca.com.
HK-12051 2025/07/09